NCT00165802View on ClinicalTrials.gov

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

January 31, 2009

Conditions
Cancer, Malignant Tumors
Interventions
DRUG

E7974

Maximum Tolerated Dose defined as 0.45 mg/m\^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.

Trial Locations (2)

33136

Sylvester Comprehensive Cancer Center - University of Miami, Miami

08903-2681

Cancer Institute Of New Jersey, New Brunswick

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00165802 - A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter